BioTuesdays

Tag - Swayampakula Ramakanth

MiMedx Group

HCW starts MiMedx at buy; PT $20

H.C. Wainwright launched coverage of MiMedx Group (NASDAQ:MDXG) with a “buy” rating and $20 price target. The stock closed at $8.81 on March 18. MiMedx is a wound care industry leader commercializing placental...

Plus Therapeutics Logo

HCW starts Plus Therapeutics at buy; PT $7

H.C. Wainwright launched coverage of Plus Therapeutics (NASDAQ:PSTV) with a “buy” rating and $7 price target. The stock closed at $3.75 on Feb. 10. Plus is focused on developing novel therapies against brain cancer. The...

Ocugen

HCW ups Ocugen to buy from neutral; PT $4.50

H.C. Wainwright upgraded Ocugen (NASDAQ:OCGN) to “buy” from “neutral” with a price target of $4.50, citing a definitive agreement with Bharat Biotech to co-develop, supply, and commercialize Bharat’s COVID-19 vaccine...

Medicenna Therapeutics

HCW starts Medicenna Therapeutics at buy; PT $8

H.C. Wainwright initiated coverage of Medicenna Therapeutics (NASDAQ:MDNA) with a “buy” rating and price target of $8. The stock closed at $3.88 on Sept. 8. Medicenna is an immuno-oncology company developing therapies...

electroCore Logo

HCW ups electroCore PT to $2.50 from $1.50

H.C. Wainwright raised its price target for electroCore (NASDAQ:ECOR) to $2.50 from $1.50, citing the FDA’s emergency use authorization of gammaCore, the company’s lead product, to treat COVID-19 patients. The stock...

Pulse Biosciences Logo

HCW ups Pulse Biosciences PT to $16 from $6

H.C. Wainwright raised its price target for Pulse Biosciences (NASDAQ:PLSE) to $16 from $6, citing the company’s agreement with the FDA on requirements for a 510(k) submission for a general dermatological indication of...

Precigen Logo

HCW starts Precigen at buy; PT $5

H.C. Wainwright initiated coverage of Precigen (NASDAQ:PGEN) with a “buy” rating and $5 price target. The stock closed at $3.17 on May 7. Precigen, previously known as Intrexon, is focused on applying synthetic biology...

PolarityTE Logo

HCW cuts PolarityTE to neutral and removes PT

H.C. Wainwright downgraded PolarityTE (NASDAQ:PTE) to “neutral” from “buy” and removed its price target, citing the clinical and regulatory risk from a strategy shift for its wound closure product, SkinTE. The stock...

AVEO Pharmaceuticals Logo

HCW cuts AVEO Pharma PT to $4 from $6

H.C. Wainwright lowered its price target for AVEO Pharmaceuticals (NASDAQ:AVEO) to $4 from $6, but reiterated a “buy” rating, citing discontinuation of the company’s ficlatuzumab program because of COVID-19 and reduced...